Found 408 clinical trials
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment
This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …
- 0 views
- 19 Feb, 2024
- 3 locations
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.
A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …
- 0 views
- 19 Feb, 2024
- 8 locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …
- 0 views
- 19 Feb, 2024
- 7 locations
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
- 0 views
- 19 Feb, 2024
- 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …
- 0 views
- 19 Feb, 2024
- 39 locations
Combination Immunotherapy Targeting Sarcomas
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines …
- 0 views
- 19 Feb, 2024
- 2 locations
Preliminary Antitumor Activity Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).
- 0 views
- 19 Feb, 2024
- 10 locations
PERSONAE - a Personalized Online Treatment of Depression
The goal of this clinical trial is to determine whether a personalized online treatment for depression, delivered via an app (PERSONAE), is effective in treating mild to moderate depression in adults. The study will also assess the safety of the Monsenso app. The main questions it aims to answer are:Does …
- 0 views
- 10 Aug, 2025
- 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
- 0 views
- 19 Feb, 2024
- 1 location
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments
Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx. The International Agency for Cancer Research of World Health Organization (WHO) classified a dozen of HPV related high-risk cancer types, and recognized cervical …
- 0 views
- 19 Feb, 2024
- 1 location